https://www.selleckchem.com/pr....oducts/Masitinib-(AB
Overall, these data provide evidence that GCs may modulate immune responses via GILZ and that GILZ is a valuable alternative for GC therapy in sepsis. © 2020 WILEY-VCH Verlag GmbH Co. KGaA, Weinheim.Ibrutinib is highly active in Waldenström macroglobulinaemia (WM) patients, but disease progression can occur due to acquired mutations in BTK, the target of ibrutinib, or PLCG2, the protein downstream of BTK. However, not all resistant patients harbour these alterations. We have performed a whole-exome sequencing study to i
Like
Comment
Share
